MedTrace Logo

Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide

NCT07777575 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-08-20

No results posted yet for this study

Summary

Incretin-based pharmacotherapies induce significant weight loss and represent a paradigm shift in obesity treatment. However, particularly fast weight loss may be accompanied by a significant loss of muscle mass, which is associated with a reduced metabolic rate at rest and during physical activity, increased insulin resistance, limited mobility, and potential long-term adverse effects. The aim of this clinical trial is to examine the effects of resistance training versus standard of care on contractile thigh muscle volume in patients receiving the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists 'tirzepatide'.

Conditions

  • Obesity (BMI>30)

Interventions

DRUG

Dual GIP/GLP-1 Receptor Agonist Tirzepatide

Tirzepatide will be titrated to a maximum tolerated dose of up to 10 mg/week (+2.5 mg/week every 4 weeks) and accomponied by regular individual diet and physical activity counseling

BEHAVIORAL

Resistance Training

Low-volume, high-intensity resistance training on 3 days/week

Sponsors & Collaborators

  • EGYM SE

    collaborator UNKNOWN

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Martin Halle, MD · Klinikum der Technischen Universität München (TUM Klinikum)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-17
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07777575 on ClinicalTrials.gov